Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment

European Journal of Radiology

Volumn 81, Issue 10, 2012, Pages 2805-2810

  Yamasaki, Fumiyuki ^a   Kurisu, Kaoru ^a   Aoki, Tomokazu ^b   Yamanaka, Masami ^c   Kajiwara, Yoshinori ^a   Watanabe, Yosuke ^a   Takayasu, Takeshi ^a   Akiyama, Yuji ^d   Sugiyama, Kazuhiko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^c Otagawa Hospital   (Japan)

^d HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bevacizumab; Diffusion weighted imaging; High b value; Pseudo response; RANO criteria

Indexed keywords

BEVACIZUMAB; GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; EARLY DIAGNOSIS; FEMALE; GLIOMA; HUMAN; IMAGING SYSTEM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CHILD; DIFFUSION MAGNETIC RESONANCE IMAGING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865252870     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2011.10.018     Document Type: Article

References (20)

1. W.B. Pope, A. Lai, P. Nghiemphu, P. Mischel, and T.F. Cloughesy MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 8 2006 1258 1260
2. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 11 2010 1963 1972
3. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 4 2007 1253 1259
4. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 2007 4722 4729
5. T. Sugahara, Y. Korogi, and M. Kochi Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas J Magn Reson Imaging 9 1 1999 53 60
6. A.R. Padhani, G. Liu, and D.M. Koh Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 2 2009 102 125
7. B.A. Moffat, T.L. Chenevert, and T.S. Lawrence Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response Proc Natl Acad Sci USA 102 15 2005 5524 5529
8. F. Yamasaki, K. Sugiyama, and M. Ohtaki Glioblastoma treated with postoperative radio-chemotherapy: prognostic value of apparent diffusion coefficient at MR imaging Eur J Radiol 73 3 2010 532 537
9. M. Cihangiroglu, B. Citci, and O. Kilickesmez The utility of high b-value DWI in evaluation of ischemic stroke at 3 T Eur J Radiol 78 2011 75 81
10. T. Yoshiura, F. Mihara, and A. Tanaka High b value diffusion-weighted imaging is more sensitive to white matter degeneration in Alzheimer's disease Neuroimage 20 1 2003 413 419
11. 2 AJNR Am J Neuroradiol 29 3 2008 458 463
12. A. Doskaliyev, F. Yamasaki, and M. Ohtaki Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3 T Eur J Radiol December 2010 [Epub ahead of print]
13. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 7 1990 1277 1280
14. A.D. Norden, J. Drappatz, and P.Y. Wen Novel anti-angiogenic therapies for malignant gliomas Lancet Neurol 7 12 2008 1152 1160
15. Y. Roth, T. Tichler, and G. Kostenich High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice Radiology 232 3 2004 685 692
16. Y. Mardor, Y. Roth, and A. Ochershvilli Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI Neoplasia 6 2 2004 136 142
17. M.C. DeLano, T.G. Cooper, J.E. Siebert, M.J. Potchen, and K. Kuppusamy High-b-value diffusion-weighted MR imaging of adult brain: image contrast and apparent diffusion coefficient map features AJNR Am J Neuroradiol 21 10 2000 1830 1836
18. T. Niendorf, R.M. Dijkhuizen, D.G. Norris, M. van Lookeren Campagne, and K. Nicolay Biexponential diffusion attenuation in various states of brain tissue: implications for diffusion-weighted imaging Magn Reson Med 36 6 1996 847 857
19. W.B. Pope, J.R. Young, and B.M. Ellingson Advances in MRI assessment of gliomas and response to anti-VEGF therapy Curr Neurol Neurosci Rep 11 3 2011 336 344
20. B.M. Ellingson, M.G. Malkin, and S.D. Rand Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity J Magn Reson Imaging 31 3 2010 538 548